Status:
COMPLETED
Comparative Effectiveness of Dapagliflozin Versus DPP-4 Inhibitors
Lead Sponsor:
University of Padova
Conditions:
Type 2 Diabetes
Eligibility:
All Genders
18-80 years
Brief Summary
Owing to their glycemic and extraglycemic effects, sodium glucose cotransporter-2 inhibitors (SGLT2i) are becoming ideal second-line agents for the treatment of type 2 diabetes (T2D). However, SGLT2i ...
Detailed Description
Background \& rationale Sodium-glucose co-transporter-2 inhibitors (SGLT2i) have become available for the treatment of type 2 diabetes (T2D) in the U.S. in April 2013 (canagliflozin), January 2014 (da...
Eligibility Criteria
Inclusion
- Diagnosis of type 2 diabetes;
- Age 18-80\*;
- Disease duration \>1 year;
- Initiation of dapagliflozin/DPP-4i in association with metformin and/or insulin.
Exclusion
- Type 1 diabetes;
- Age \<18 or \>80\*;
- Previous or ongoing therapy with another SGLT2i;
- CKD (eGFR \<60 ml/min/1.73 mq)
Key Trial Info
Start Date :
October 18 2018
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
February 29 2020
Estimated Enrollment :
11206 Patients enrolled
Trial Details
Trial ID
NCT04304430
Start Date
October 18 2018
End Date
February 29 2020
Last Update
March 11 2020
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University Hospital of Padova
Padua, Italy, 35128